A biotechnology company making headlines for its work in organ transplantation is planning to construct an estimated $96 million facility in northeast Houston to breed genetically engineered animals, ...

The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by several headwinds ...

Eli Lilly is to buy the private biotech Disarm Therapeutics, which is working on a new class of disease-modifying drugs for neurological diseases, in a deal worth up to $1.36 billion.